Indication

In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens

Medicine details

Medicine name:
tucatinib (Tukysa)
SMC ID:
SMC2398
Pharmaceutical company
Seagen
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
04 October 2021